Content
June 2006, Volume 7, Issue 2
- 89-90 Pharmaceutical policy in Italy
by Livio Garattini & Dante Cornago - 91-98 The reasons of general practitioners for promoting colorectal cancer mass screening in France
by Célia Berchi & Jean-Marc Dupuis & Guy Launoy - 99-106 Choices and utilization in dental care
by Lien Nguyen & Unto Häkkinen - 107-113 Economic impact of simplified de Gramont regimen in first-line therapy in metastatic colorectal cancer
by Samuel Limat & Claire-Hélène Bracco-Nolin & Christine Legat-Fagnoni & Loic Chaigneau & Ulrich Stein & Bernard Huchet & Xavier Pivot & Marie-Christine Woronoff-Lemsi - 114-116 Health care and patients’ migration across Spanish regions
by David Cantarero - 117-122 The future of imaging techniques for cancer patients in The Netherlands
by Theo Postma & Janneke Alers & Sijmon Terpstra & Arjan Zuurbier - 123-128 Factors influencing the costs of emergency medical admissions to an Irish teaching hospital
by Edward Moloney & Kathleen Bennett & Bernard Silke - 129-136 Outcomes research collaborations between third-party payers, academia, and pharmaceutical manufacturers
by Hans-Georg Eichler & Sheldon Kong & Jean-Pierre Grégoire - 137-144 Cost-effectiveness of memantine in community-based Alzheimer’s disease patients: an adaptation in Spain
by Fernando Antonanzas & Benoit Rive & Josep Badenas & Susana Gomez-Lus & Chantal Guilhaume - 145-146 Costs of chemotherapy in the treatment of colorectal cancer
by F. Jansman & M. Postma - 147-151 A taxonomy of health utility assessment methods and the role for uncertainty analysis
by Agota Szende & Caroline Schaefer
March 2006, Volume 7, Issue 1
- 5-6 The desirability and feasibility of economic studies of drugs post-launch
by Michael Drummond & Anne Mason & Adrian Towse - 7-18 The relationship between health care expenditure and health outcomes
by John Nixon & Philippe Ulmann - 19-29 Pharmacoeconomic modelling in schizophrenia
by Karina Hansen & Christophe Lançon & Mondher Toumi - 30-36 Comparing costs and effectiveness of different starting points for highly active antiretroviral therapy in HIV-positive patients
by Monica Merito & Patrizio Pezzotti - 37-45 Fixed budgets as a cost containment measure for pharmaceuticals
by David Granlund & Niklas Rudholm & Magnus Wikström - 46-54 The Danish effect on Swedish alcohol costs
by Johan Jarl & Ulf-G. Gerdtham & Carl Lyttkens & Thor Lithman & Juan Merlo - 55-65 Prospective casemix-based funding, analysis and financial impact of cost outliers in all-patient refined diagnosis related groups in three Belgian general hospitals
by Magali Pirson & Dimitri Martins & Terri Jackson & Michèle Dramaix & Pol Leclercq - 66-71 Case-control analysis of the financial cost of medication errors in hospitalized patients
by Jaime Pinilla & Carles Murillo & Genís Carrasco & Carlos Humet - 72-78 Cost-utility analysis comparing meropenem with imipenem plus cilastatin in the treatment of severe infections in intensive care
by Steven Edwards & Helen Campbell & Jonathan Plumb - 79-83 Off-patent drugs in Italy
by Livio Garattini & Simone Ghislandi
December 2005, Volume 6, Issue 4
- 285-287 How much are health-care systems prepared to pay to produce a QALY?
by Martin Buxton - 288-297 Trial-based cost-utility comparison of percutaneous myocardial laser revascularisation and continued medical therapy for treatment of refractory angina pectoris
by Helen Campbell & Sue Tait & Linda Sharples & Noreen Caine & Timothy Gray & Peter Schofield & Martin Buxton - 298-308 Does testing for prostate-specific antigen contribute to declining prostate cancer mortality?
by L. Di Matteo & R. Di Matteo - 309-313 Indirect costs of cervical and breast cancers in Spain
by Juan Oliva & Félix Lobo & Julio López-Bastida & Néboa Zozaya & Rosa Romay - 314-316 Discrete choice experiments in health economics: Distinguishing between the method and its application
by Emily Lancsar & Cam Donaldson - 317-321 Cost-effectiveness of outpatient treatment in depressive patients with escitalopram in Germany
by Werner Kulp & J.-M. Schulenburg & Wolfgang Greiner - 322-333 Hospital development plans
by Steffen Fleßa - 334-346 Can economic evaluations be made more transferable?
by Stephanie Boulenger & John Nixon & Michael Drummond & Philippe Ulmann & Stephen Rice & Gerard Pouvourville - 347-353 Estimating utility data from clinical indicators for patients with stable angina
by Louise Longworth & Martin Buxton & Mark Sculpher & David Smith - 354-362 The cost-effectiveness of dual oral antiplatelet therapy following percutaneous coronary intervention
by Anna Ringborg & Peter Lindgren & Bengt Jönsson
September 2005, Volume 6, Issue 3
- 191-196 Health economic evaluation of disease management programs
by Wolfgang Greiner - 197-202 The economic and quality of life impact of hypoglycemia
by Jonas Lundkvist & Christian Berne & Björn Bolinder & Linus Jönsson - 203-214 Use of a decision analysis model to assess the medicoeconomic implications of FDG PET imaging in diagnosing a solitary pulmonary nodule
by Catherine Lejeune & Kazem Al Zahouri & Marie-Christine Woronoff-Lemsi & Patrick Arveux & Alain Bernard & Christine Binquet & Francis Guillemin - 215-222 Institutional arrangements and efficiency of health care delivery systems
by Vasanthakumar Bhat - 223-232 A cross-national perspective on cost of illness
by Johan Polder & Willem Meerding & Luc Bonneux & Paul Maas - 233-243 An empirical analysis of tobacco addiction in Italy
by Silvia Tiezzi - 244-252 Influenza treatment with neuraminidase inhibitors
by Beate Sander & Marlene Gyldmark & Frederick Hayden & James Morris & Elvira Mueller & Rito Bergemann - 253-260 Measuring health-related utility:
by Stirling Bryan & Louise Longworth - 261-266 Comparison of general practitioner records and patient self-report questionnaires for estimation of costs
by Hema Mistry & Martin Buxton & Louise Longworth & Judy Chatwin & Robert Peveler - 267-273 The potential impact of implementing a system of generic substitution on the community drug schemes in Ireland
by Lesley Tilson & Kathleen Bennett & Michael Barry - 274-279 Reimbursement and clinical guidance for pharmaceuticals in Sweden
by Anders Anell & Ulf Persson
June 2005, Volume 6, Issue 2
- 91-93 Practice guidelines based on clinical and economic evidence
by Frans Rutten & Werner Brouwer & Louis Niessen - 94-101 Costs of hospitalization for severe acute asthma of patients not treated according to guidelines and recommendations
by Jean-Claude Sailly & Xavier Lenne & Caroline Bercez & Thérèse Lebrun & Antoine-Bernard Tonnel & Isabelle Tillie-Leblond - 102-106 Cost of home palliative care compared with conventional hospital care for patients with haematological cancers in Greece
by Sofia Tzala & Joanne Lord & Nikolaos Ziras & Panayotis Repousis & Anna Potamianou & Evangelia Tzala - 107-111 Time preference bias in time trade-off
by Marjon Pol & Larissa Roux - 112-123 Using competence network collaboration and decision-analytic modeling to assess the cost-effectiveness of interferon α-2b plus ribavirin as initial treatment of chronic hepatitis C in Germany
by Uwe Siebert & Gaby Sroczynski & Jürgen Wasem & Wolfgang Greiner & Ulrike Ravens-Sieberer & Pamela Aidelsburger & Bärbel Kurth & Monika Bullinger & J.-Matthias Schulenburg & John Wong & Siegbert Rossol - 124-130 Validating the EQ-5D with time trade off for the German population
by W. Greiner & C. Claes & J. J. V. Busschbach & J.-M. Schulenburg - 131-135 Spatial competition for quality in the market for hospital care
by Marcello Montefiori - 136-145 Cost-effectiveness of venlafaxine XL compared with diazepam in the treatment of generalised anxiety disorder in the United Kingdom
by J. Guest & J. Russ & A. Lenox-Smith - 146-151 Order bias in estimates of willingness to pay for drugs to treat attention-deficit/hyperactivity disorder
by Annemieke De Ridder & Diana De Graeve - 152-158 Risk and potential risk reduction in diabetes type 2 patients in Germany
by Bertram Häussler & Ursula Berger & Oliver Mast & Wolfgang Thefeld - 159-165 Economic burden of hepatitis C in Canada and the potential impact of prevention
by Susie El Saadany & Douglas Coyle & Antonio Giulivi & Mohammad Afzal - 166-171 The direct medical cost of diabetes in Israel
by Gabriel Chodick & Anthony Heymann & Francis Wood & Ehud Kokia - 172-182 The cost-effectiveness of prophylaxis with valaciclovir in the management of cytomegalovirus after renal transplantation
by Christophe Legendre & Stephen Beard & Anne Crochard & Yvon Lebranchu & Claire Pouteil-Noble & Anke Richter & Isabelle Durand-Zaleski - 183-187 German health care system in transition
by J.-Matthias Schulenburg
March 2005, Volume 6, Issue 1
- 2-7 Criteria for determining a basic health services package
by E. Stolk & M. Poley - 8-15 Consumer preferences in social health insurance
by Jan Kerssens & Peter Groenewegen - 16-23 Modeling the economic burden of diseases imputable to stress at work
by Sophie Béjean & Hélène Sultan-Taïeb - 30-37 The cost-effectiveness of human papillomavirus screening for cervical cancer
by Jeremy Holmes & Lindsay Hemmett & Susan Garfield - 38-44 Collecting unit cost data in multicentre studies
by Sarah Wordsworth & Anne Ludbrook & Fergus Caskey & Alison Macleod - 45-52 Bayesian regression models for cost-effectiveness analysis
by Francisco-José Polo & Miguel Negrín & Xavier Badía & Montse Roset - 53-64 Substance abuse treatment, what do we know?
by Matilde Machado - 65-72 A modified three-stage data envelopment analysis
by Jos Blank & Vivian Valdmanis - 73-82 A ‘new and improved’ EQ-5D valuation questionnaire?
by Nancy Devlin & Paul Hansen & Peter Herbison & Susan Macran - 83-86 On the (mis)use of cross-price effects to gauge the effectiveness of smokeless tobacco in smoking cessation
by Richard Ault & T. Beard & John Jackson & Richard Saba
November 2005, Volume 6, Issue 1
- 2-10 Defining the “Health Benefit Basket” in nine European countries
by J. Schreyögg & T. Stargardt & M. Velasco-Garrido & R. Busse - 11-17 The “Health Benefit Basket” in Denmark
by Lone Bilde & Anni Ankjaer-Jensen & Bent Danneskiold-Samsøe - 18-23 Does the English NHS have a ‘Health Benefit Basket’?
by Anne Mason - 24-29 The “Health Benefit Basket” in France
by Martine Bellanger & Veneta Cherilova & Valérie Paris - 30-36 Determining the “Health Benefit Basket” of the Statutory Health Insurance scheme in Germany
by Reinhard Busse & Tom Stargardt & Jonas Schreyögg - 37-45 Benefits and entitlements in the Hungarian health care system
by Peter Gaal - 46-52 The “Essential Levels of Care” in Italy: when being explicit serves the devolution of powers
by Aleksandra Torbica & Giovanni Fattore - 53-57 The “Health Benefit Basket” in The Netherlands
by Elly Stolk & Frans Rutten - 58-65 Definition of the “Health Benefit Basket” in Poland
by Adam Kozierkiewicz & Wojciech Trąbka & Artur Romaszewski & Krzysztof Gajda & Dariusz Gilewski - 66-72 Spanish health benefits for services of curative care
by Ivan Planas-Miret & Ana Tur-Prats & Jaume Puig-Junoy
November 2004, Volume 5, Issue 4
- 287-289 Using diagnosis-related groups
by M. Lungen & B. Dredge & A. Rose & C. Roebuck & E. Plamper & K. Lauterbach - 290-298 Re-scaling social preference data: implications for modelling
by Irina Cleemput & Paul Kind & Katrien Kesteloot - 299-308 Willingness to pay for dental fear treatment
by Bente Halvorsen & Tiril Willumsen - 309-316 What reimbursement for coronary revascularization with drug-eluting stents?
by Rosanna Tarricone & Monia Marchetti & Mark Lamotte & Lieven Annemans & Peter Jong - 317-323 A method for cross-sector priority setting
by Tugrul Temel - 324-329 Drug price regulation under consumer moral hazard
by Stefan Felder - 330-334 Direct medical costs of monitoring and treating patients with Takayasu arteritis in Italy
by Iva Krulichova & Sara Gamba & Elena Ricci & Livio Garattini - 335-340 A note on the impact of hours worked on mortality in OECD countries
by Edvard Johansson - 341-344 The high cost of medicines in Ireland
by Lesley Tilson & Bernadette McGowan & Kathleen Bennett & Michael Barry - 345-350 Approval times and the safety of new pharmaceuticals
by Niklas Rudholm - 351-356 Examining the quality of health economic analyses submitted to the Pharmaceutical Benefits Board in Sweden
by Joakim Ramsberg & Stefan Odeberg & Andreas Engström & Douglas Lundin - 357-364 Data envelopment analysis based bonus payments
by Stefan Felder & Horst Schmitt - 365-367 Exponential health utility
by Lars Østerdal
September 2004, Volume 5, Issue 3
- 199-202 Discrete choice experiments in health economics
by Stirling Bryan & Paul Dolan - 203-208 Side effects of generic competition?
by Jörgen Hellström & Niklas Rudholm - 209-215 Estimating rural households’ willingness to pay for health insurance
by Ali Asgary & Ken Willis & Ali Taghvaei & Mojtaba Rafeian - 216-226 Measuring and comparing the (in)efficiency of German and Swiss hospitals
by Lukas Steinmann & Gunnar Dittrich & Alexander Karmann & Peter Zweifel - 227-235 Costs and consequences of botulinum toxin type A use
by Francis Ruiz & Julian Guest & Almut Lehmann & Alison Davie & Karen Güttler & Olaf Schlüter & Götz Dreiss - 236-242 Economics and health promotion
by Luke Connelly - 243-251 The cost structure of lung tuberculosis in Germany
by Roland Diel & Bernhard Rappenhöner & Tom Schaberg - 252-258 Financing of health care services in Hungary
by Imre Boncz & Júlia Nagy & Andor Sebestyén & László Kőrösi - 259-262 Health care provider payment mechanisms in the new EU members of Central Europe and the Baltic states
by Agota Szende & Zsolt Mogyorosy - 263-269 Reimbursement of glitazones in treatment of type 2 diabetes patients in Denmark in the context of a voluntary system for submitting pharmacoeconomic studies
by Hindrik Vondeling & Peter Iversen - 270-273 Costs of treatment of colorectal cancer in different settings in Germany
by Klaus Hieke & Ulrich Kleeberg & Martina Stauch & Axel Grothey - 274-277 Out-patient drug policy by clinical assessment rather than financial constraints?
by Marja Pronk & Gouke Bonsel - 278-284 A pharmacoeconomic evaluation of the effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes in Spain
by Juan Gómez-Gerique & Roman Casciano & Lee Stern & Javier Rejas
May 2004, Volume 5, Issue 2
- 95-109 The risk-adjusted vision beyond casemix (DRG) funding in Australia
by Kathryn Antioch & Michael Walsh - 110-115 Pricing of pharmaceuticals
by Mark Nuijten & Joszef Kosa - 115-115 The risk-adjusted vision beyond casemix (DRG) funding in Australia
by Kathryn Antioch & Michael Walsh - 116-121 Genetic screening, health care and the insurance industry
by Diego Ossa & Adrian Towse - 122-128 Price-cost margin in the pharmaceutical industry
by Ismo Linnosmaa & Raine Hermans & Taru Hallinen - 129-135 Model for simulation of HIV/AIDS and cost-effectiveness of preventing non-tuberculous mycobacterial (MAC)-disease
by Thomas Hoffmann & Helmut Brunner - 136-142 Potential cost-effectiveness of a family-based program in mild Alzheimer’s disease patients
by Janne Martikainen & Hannu Valtonen & Tuula Pirttilä - 143-149 Economic evaluation of a combined DTPa, hepatitis B, polio, Hib vaccine
by Francis Fagnani & Camille Fur & Isabelle Durand & Michel Gibergy - 150-165 An empirical analysis of the demand for physician services across the European Union
by Sergi Jiménez-Martín & José Labeaga & Maite Martínez-Granado - 166-174 Economic growth, longevity and the epidemiological transition
by Olivier Morand - 175-182 Dynamic competition in pharmaceuticals
by Laura Magazzini & Fabio Pammolli & Massimo Riccaboni - 183-187 The European Network of Health Economic Evaluation Databases (EURO NHEED) Project
by John Nixon & Philippe Ulmann & Julie Glanville & Stéphanie Boulenger & Michael Drummond & Gérard Pouvourville - 188-189 “Economic evaluation of gemcitabine in the treatment of pancreatic cancer in the UK”
by Nick Bansback & Sue Ward & Jon Karnon - 190-194 Pricing and reimbursement of drugs in Ireland
by Michael Barry & Lesley Tilson & Máirín Ryan
February 2004, Volume 5, Issue 1
- 6-14 Evaluating the effect of care programs for elderly persons with dementia on caregiver’s well-being
by Agnes Gramain & Laëtitia Malavolti - 15-21 Direct medical costs unequivocally related to diabetes in Italian specialized centers
by Livio Garattini & Francesca Chiaffarino & Dante Cornago & Carlo Coscelli & Fabio Parazzini - 22-27 Direct medical costs of age-related macular degeneration in Italian hospital ophthalmology departments
by Livio Garattini & Emanuela Castelnuovo & Paolo Lanzetta & Cecilia Viscarra & Elena Ricci & Fabio Parazzini - 28-35 Priority setting for pharmaceuticals
by Anders Anell - 36-45 Economic valuation of informal care
by Bernard Berg & Werner Brouwer & Marc Koopmanschap - 45-45 An exponential representation of health state utility
by Michael Happich & Axel Muehlbacher - 46-53 The burden of varicella in Germany
by Kurt Banz & Stefan Wagenpfeil & Albrecht Neiss & Thomas Hammerschmidt & Peter Wutzler - 54-57 Do costs of varicella justify routine infant vaccination?
by M. Postma & J. Bos & R. Welte & R. Groot & W. Luytjes & H. Rümke & P. Beutels - 58-63 Economic evaluation and survival analysis of immunoglobulin adsorption in patients with idiopathic dilated cardiomyopathy
by Franz Hessel & Christoph Wegner & Johannes Müller & Christina Glaveris & Jürgen Wasem - 64-69 Comparison of estimated medical costs among patients who are defined as having rheumatoid arthritis using three different standards
by Jörg Ruof & Jan Hülsemann & Thomas Mittendorf & Silke Handelmann & Rick Aultman & J. Schulenburg & Henning Zeidler & Sonja Merkesdal - 70-80 Economic burden of head and neck cancer
by Jennifer Lee & Marco Turini & Marc Botteman & Jennifer Stephens & Chris Pashos - 81-86 Chained time trade-off and standard gamble methods
by Paul McNamee & Sharon Glendinning & Jonathan Shenfine & Nick Steen & S. Griffin & John Bond
October 2004, Volume 5, Issue 1
- 4-4 A review of European studies on the economic burden of brain diseases
by Bengt Jönsson & Jes Olesen - 5-12 Economic evidence in addiction: a review
by Patrik Andlin-Sobocki - 12-20 Economic evidence in affective disorders: a review
by Mickael Löthgren - 20-25 Economic evidence in anxiety disorders: a review
by Mickael Löthgren - 25-30 Economic evidence in brain tumour: a review
by Mattias Ekman - 30-35 Economic evidence in dementia: a review
by Linus Jönsson - 36-42 Economic evidence in epilepsy: a review
by Mattias Ekman & Lars Forsgren - 43-54 Economic evidence in migraine and other headaches: a review
by Jenny Berg - 54-62 Economic evidence in multiple sclerosis: a review
by Gisela Kobelt - 63-66 Economic evidence in parkinson’s disease: a review
by Peter Lindgren - 67-74 Economic evidence in psychotic disorders: a review
by Mickael Löthgren - 74-83 Economic evidence in stroke: a review
by Mattias Ekman - 84-91 Economic evidence in trauma: a review
by Jenny Berg
December 2003, Volume 4, Issue 4
- 248-253 Economic burden of obesity and its complications in Germany
by Beate Sander & Rito Bergemann - 254-262 Cost-effectiveness of fondaparinux vs. enoxaparin as venous thromboembolism prophylaxis in Sweden
by Jonas Lundkvist & David Bergqvist & Bengt Jönsson - 263-270 Should one use smokeless tobacco in smoking cessation programs?
by Mikael Bask & Maria Melkersson - 271-278 A Markov model of treatment of newly diagnosed epilepsy in the UK
by E. Remák & J. Hutton & M. Price & K. Peeters & I. Adriaenssen - 279-285 Financial incentives and the supply of laboratory tests
by Fredrik Carlsen & Jostein Grytten & Irene Skau - 286-291 Health care reform in six Central European countries
by Mark Nuijten & Agota Szende & Jozsef Kosa & Zsolt Mogyorosy & Boris Kramberger & Karel Nemecek & Dominik Tomek & Stjepan Oreskovic & Monika Laskowska - 292-294 An exponential representation of health state utility
by Michael Happich & Axel Muehlbacher - 295-295 Testing assumptions of quality-adjusted life-year calculations
by Ariel Béresniak - 296-303 Project of Polish guidelines for conducting pharmacoeconomic evaluations in comparison to international health economic guidelines
by Ewa Orlewska & Piotr Mierzejewski - 304-312 Modeling risk-adjusted capitation rates for Umbria, Italy
by Elaine Yuen & Daniel Louis & Paolo Loreto & Joseph Gonnella - 313-318 The lag between effectiveness and cost-effectiveness evidence of new drugs
by Boyka Stoykova & Michael Drummond & Marco Barbieri & Jos Kleijnen - 319-326 Measles dynamics and vaccination diffusion
by Laurent Coudeville - 327-333 An overview of the Greek pharmaceutical market
by V. Kontozamanis & E. Mantzouneas & C. Stoforos
September 2003, Volume 4, Issue 3
- 143-150 When should decision-analytic modeling be used in the economic evaluation of health care?
by Uwe Siebert - 151-157 Pharmaceutical expenditure in Spain: evolution and cost containment measures during 1998–2001
by Josep Darbà - 158-175 A fuzzy logic approach toward solving the analytic enigma of health system financing
by Dov Chernichovsky & Arkady Bolotin & David Leeuw - 176-183 Scale of reference bias and the evolution of health
by Wim Groot - 184-194 Is therapeutic innovation responsible for the increase in drug expenditure?
by Philippe Cavalié - 195-202 Time to disable DALYs?
by Carl Lyttkens - 203-208 Costs and effectiveness of a syringe distribution and needle exchange program for HIV prevention in a regional setting
by Juan Cabasés & Eduardo Sánchez - 209-215 Economic evaluation of human papillomavirus screening in Germany
by T. Mittendorf & K. Petry & T. Iftner & W. Greiner & J. Schulenburg - 216-221 Economic evaluation of gemcitabine in the treatment of pancreatic cancer in the UK
by Mike Aristides & Michael Lees & Nick Botwood & Jan McKendrick & Deborah Stephenson & Nikos Maniadakis - 222-231 A single European currency for EQ-5D health states
by Wolfgang Greiner & Tom Weijnen & Martin Nieuwenhuizen & Siem Oppe & Xavier Badia & Jan Busschbach & Martin Buxton & Paul Dolan & Paul Kind & Paul Krabbe & Arto Ohinmaa & David Parkin & Montserat Roset & Harri Sintonen & Aki Tsuchiya & Frank Charro - 232-238 The efficiency of treatment strategies of general practitioners
by Matthias Staat - 239-240 Commentary on Coyle et al., "The assessment of the economic return from controlled clinical trials"
by Jon Karnon & A. Brennan & J. Chilcott
September 2002, Volume 3, Issue 3
- 145-148 Measuring health system performance
by P.C. Smith - 149-155 Budget impact model for determining the costs of introducing inhaled salmeterol/fluticasone propionate combination for the management of persistent asthma in France
by B. Detournay & C. Pribil & C. Jourdanne & M. Price - 156-165 Disease progression in amyotrophic lateral sclerosis
by M. Tavakoli - 166-172 Costs of toxicity during chemotherapy with CHOP, COP/CVP, and fludarabine
by M. Herold & K. Hieke - 173-179 A pharmacoeconomic evaluation of zuclopenthixol compared with haloperidol and risperidone in the treatment of schizophrenia
by K. Hansen & C. François & M. Toumi & C. Lançon - 180-187 Modelling the costs and effects of leflunomide in rheumatoid arthritis
by G. Kobelt & P. Lindgren & A. Young - 188-195 Medical savings accounts: a core feature of Singapore's health care system
by W. von Eiff & T. Massoro & Y. O. Voo & R. Ziegenbein - 196-206 Methodological guidelines for conducting economic evaluation of healthcare interventions in Hungary: a Hungarian proposal for methodology standards
by Ágota Szende & Z. Mogyorósy & N. Muszbek & J. Nagy & G. Pallos & C Dözsa - 207-214 Restructuring of the healthcare system and the diffusion of telemedicine
by M. Kerleau & N. Pelletier-Fleury - 215-220 Pricing and reimbursement of pharmaceuticals in Norway
by A. Hågå & J. M. Sverre
June 2002, Volume 3, Issue 2
- 73-76 Genetic testing and the health care system
by Oliver Schöffski - 77-82 Burden of illness imposed by severe sepsis in Germany
by A. Schmid & H. Burchardi & J. Clouth & H. Schneider - 83-93 Risk-adjusted capitation funding models for chronic disease in Australia: alternatives to casemix funding
by K. M. Antioch & M.K. Walsh - 94-102 The epidemiology, economics and quality of life burden of age-related macular degeneration in France, Germany, Italy and the United Kingdom
by J. Bonastre & C. Le Pen & P. Anderson & A. Ganz & P. Berto & G. Berdeaux - 103-110 Reputation, public information, and physician adoption of an innovation
by J. G. Smythe - 111-119 Costs of opioid therapy for chronic nonmalignant pain in Germany: an economic model comparing transdermal fentanyl (Durogesic) with controlled-release morphine
by Lukas Radbruch & K. Lehmann & H.-H. Gockel & D. Neighbors & G. Nuyts - 120-124 Association of time preference for health with age and disease severity
by K. Stavem & I. S. Kristiansen & J. A. Olsen - 124-124 Erratum to: Does health technology assessment benefit health services and politics?
by H. Sigmund & F.B. Kristensen - 125-130 Is EQ-5D a valid measure of HRQoL in patients with movement disorders?
by S. Ghislandi & G. Apolone & L. Garattini & I. Ghislandi - 131-136 Developing a scoring system to quality assess economic evaluations
by J. G. Gonzalez-Perez - 137-138 Time for a change in drug licensing requirements?
by Michael F. Drummond - 138-138 Commentary
by J.-Matthias Graf Schulenburg - 139-139 Commentary
by Bengt Jönsson - 140-141 Time for a change in drug pricing : Going downstream
by Gérard Pouvourville - 141-142 Drug licensing requirements are changing!
by F. Lekkerkerker & F. Rutten - 142-142 A final comment
by Michael F. Drummond
March 2002, Volume 3, Issue 1
- 3-9 Costing hospital activity: the experience with healthcare resource groups in England
by A. Street & D. Dawson - 10-16 Comparing the results of applying different methods of eliciting time preferences for health
by Dorte Gyrd-Hansen - 17-25 Devolved budgetary responsibility in primary care
by P. Wilton & R. D. Smith - 26-39 Integrating cost-effectiveness evidence into clinical practice guidelines in Australia for acute myocardial infarction
by K. M. Antioch & G. Jennings & M. Botti & R. Chapman & V. Wulfsohn - 40-46 Priorities and Prospect Theory
by M. Happich & B. Mazurek - 47-53 Adapting portfolio theory for the evaluation of multiple investments in health with a multiplicative extension for treatment synergies
by J. F. P. Bridges & M. Stewart & M. T. King & K. van Gool